EMA Authorised: Simulect (basiliximab) — Novartis Europharm Limited

View source ↗

Summary

The EMA has authorised Simulect (basiliximab) for use in preventing graft rejection in kidney transplantation, with Novartis Europharm Limited as the marketing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Transplantation

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection;Kidney Transplantation. MAH: Novartis Europharm Limited. Decision date: 18/12/2025